Melbourne, Australia, 05 October 2017: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to present at the European Retinal Meeting in Paris.
OccuRx has been accepted for both an oral and poster presentation at the scientific meeting between 5th -7th October 2017.
The presentation is titled ‘The protective effect of OCX063 on reducing neovascularization and lesion size in a mouse model of choroidal neovascularization’.
The first presentation is titled ‘The protective effect of OCX063 on reducing neovascularization and lesion size in a mouse model of choroidal neovascularization’. The presentation will highlight the effect of OCX063 has on choroidal neovascularization (CNV) in an experimental animal model. The results show that OCX063 reduced CNV lesion size and leakage at 7 days and 30 days and may provide an alternative treatment for wet age-related macular degeneration (AMD) patients especially those that do not respond to anti-VEGF therapies.
“It’s exciting for OccuRx to feature at such an important event in the ocular space and present our OCX063 data that has anti-Inflammatory and anti-fibrotic properties in retinal cultures.” said Professor Darren Kelly, Executive Chair of OccuRx.
